CA2901394A1 - Growth differentiation factor (gdf) for treatment of diastolic heart failure - Google Patents

Growth differentiation factor (gdf) for treatment of diastolic heart failure Download PDF

Info

Publication number
CA2901394A1
CA2901394A1 CA2901394A CA2901394A CA2901394A1 CA 2901394 A1 CA2901394 A1 CA 2901394A1 CA 2901394 A CA2901394 A CA 2901394A CA 2901394 A CA2901394 A CA 2901394A CA 2901394 A1 CA2901394 A1 CA 2901394A1
Authority
CA
Canada
Prior art keywords
gdf11
polypeptide
seq
level
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2901394A
Other languages
English (en)
French (fr)
Inventor
Richard T. Lee
Francesco LOFFREDO
James PANCOAST
Matthew STEINHAUSER
Amy Wagers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Brigham and Womens Hospital Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Harvard University filed Critical Brigham and Womens Hospital Inc
Publication of CA2901394A1 publication Critical patent/CA2901394A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2901394A 2012-03-19 2013-03-11 Growth differentiation factor (gdf) for treatment of diastolic heart failure Pending CA2901394A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261612550P 2012-03-19 2012-03-19
US61/612,550 2012-03-19
US201261649962P 2012-05-22 2012-05-22
US61/649,962 2012-05-22
PCT/US2013/030140 WO2013142114A1 (en) 2012-03-19 2013-03-11 Growth differentiation factor (gdf) for treatment of diastolic heart failure

Publications (1)

Publication Number Publication Date
CA2901394A1 true CA2901394A1 (en) 2013-09-26

Family

ID=49223184

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2901394A Pending CA2901394A1 (en) 2012-03-19 2013-03-11 Growth differentiation factor (gdf) for treatment of diastolic heart failure

Country Status (6)

Country Link
US (1) US9434779B2 (https=)
EP (1) EP2828289B1 (https=)
JP (1) JP6124986B2 (https=)
CA (1) CA2901394A1 (https=)
ES (1) ES2779698T3 (https=)
WO (1) WO2013142114A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN103415624B (zh) 2010-08-13 2017-03-01 私募蛋白质体公司 胰腺癌生物标记及其用途
ES2777002T3 (es) * 2011-09-30 2020-08-03 Somalogic Inc Predicción de eventos de riesgo cardiovascular y usos de la misma
ES2924479T3 (es) * 2013-04-08 2022-10-07 Harvard College Composiciones para rejuvenecer las células madre del músculo esquelético
US20160220640A1 (en) * 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
WO2015073396A1 (en) * 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
WO2015176066A2 (en) * 2014-05-16 2015-11-19 Intermune, Inc. Lpa-associated protein and rna expression
US20170298128A1 (en) * 2014-09-23 2017-10-19 President And Fellows Of Harvard College Methods and compositions for treating age-related disorders
BR112017008476B1 (pt) 2014-11-24 2024-03-12 Somalogic Operating Co., Inc Aptâmero que se liga ao fator de diferenciação de crescimento 11 (gdf11), composição, método de detecção de gdf11 em uma amostra ou de determinar se a amostra compreende gdf11 e kit
CA3001536A1 (en) 2015-12-28 2017-07-06 Riken Compositions for use in recovering or ameliorating deterioration of physiological functions due to aging
CA3010799A1 (en) * 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
WO2019144053A1 (en) * 2018-01-19 2019-07-25 President And Fellows Of Harward College Gdf11 variants and uses thereof
US20200222459A1 (en) * 2019-01-16 2020-07-16 Melvin Barnes System, Method and Compositions for Treating Age-Related Illnesses and Conditions
JP2022001603A (ja) * 2021-10-14 2022-01-06 功 加治佐 自分由来ｉＰＳ若い血液応用ＧＤＦ１１分子コーティング若返り経口不老不死薬９
CN114989310B (zh) * 2022-06-20 2024-11-19 深圳先进技术研究院 一种嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及应用
CN115212299B (zh) * 2022-06-21 2026-02-24 深圳先进技术研究院 Car-t和car-m联用在制备抗肿瘤药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4612302A (en) 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1994026892A1 (en) * 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6008434A (en) * 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
WO1998054572A1 (en) 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20070155661A1 (en) 2003-02-14 2007-07-05 The Board Of Trustees Of The Leland Standord Junior University Methods and compositions for modulating the development of stem cells
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
WO2006096515A2 (en) 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CA2652549A1 (en) 2006-05-17 2007-12-13 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
US7947646B2 (en) * 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
WO2009142678A1 (en) 2008-03-27 2009-11-26 Promega Corporatin Protein labeling with cyanobenzothiazole conjugates

Also Published As

Publication number Publication date
JP6124986B2 (ja) 2017-05-10
JP2015512387A (ja) 2015-04-27
EP2828289A1 (en) 2015-01-28
EP2828289B1 (en) 2020-02-26
ES2779698T3 (es) 2020-08-18
WO2013142114A1 (en) 2013-09-26
US9434779B2 (en) 2016-09-06
EP2828289A4 (en) 2016-01-06
US20150045297A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
EP2828289B1 (en) Growth differentiation factor (gdf) 11 for treatment of age-related cardiovascular condition
US11612639B2 (en) Methods and compositions for rejuvenating skeletal muscle stem cells
US20200317767A1 (en) Growth differentiation factor (gdf) for treatment of diastolic heart failure
US11725033B2 (en) GDF11 variants and uses thereof
Song et al. CREG protects from myocardial ischemia/reperfusion injury by regulating myocardial autophagy and apoptosis
Zhou et al. Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model
EP2763688B1 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
WO2016118859A1 (en) Compositions and methods for selectively depleting senescent cells comprising flip
WO2012159107A1 (en) Inhibition of renal fibrosis
US20190365858A1 (en) Methods and compositions for rejuvenating neuromuscular junctions
Ding et al. Cellular delivery of relaxin-2 mRNA as a potential treatment for kidney fibrosis
US11529391B2 (en) Reversing deficient hedgehog signaling restores deficient skeletal regeneration
KR102785286B1 (ko) 특발성 폐 섬유증의 약물 표적
US20220062299A1 (en) Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20240382561A1 (en) Glucoregulatory compound, composition and uses thereof
US20250129093A1 (en) Compositions and methods relating to atp/p2x7r signaling inhibition
HK40091706A (zh) 葡萄糖调节化合物、其组合物和其用途
Wang et al. pathways, mTORC1 and Abl, in β Noncanonical TGF

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180213

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240717

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250129

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250306

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250318

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260306

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260306